Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02766023 · ClinicalTrials.gov registry record · Phase 2
LACTIN-V Study for Recurrent Bacterial Vaginosis
A Phase 2 study of Bacterial Vaginosis, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 228
- Enrollment target
- 4
- Study locations
NCT02766023 is a Phase 2 study of Bacterial Vaginosis that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 228 participants, below the 323-participant average among 15 other Bacterial Vaginosis trials with a reported enrollment target (29% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT02766023, a Phase 2 study of Bacterial Vaginosis, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 228 participants
- Enrollment target
- 4
- Study locations
Study Summary
This Phase 2b trial is designed to provide a screening evaluation for the hypothesis that, following a 5-day treatment with MetroGel® to treat BV, L. crispatus CTV-05 (LACTIN-V, Osel, Inc.) administered at 2 x 10\^9 cfu/dose using a vaginal applicator reduces the 12-week incidence of BV recurrence when compared to placebo. The primary objectives of this study are: 1) To estimate the efficacy of repeated doses of LACTIN-V (2 x 10\^9 cfu/dose) as compared to placebo in preventing BV recurrence by 12 weeks following treatment of BV with MetroGel vaginal gel (MetroGel). 2) To assess the safety of LACTIN-V over 24 weeks by comparing the incidence of AEs between individuals randomized to LACTIN-V or placebo.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Metronidazole
- BIOLOGICAL Lactobacillus crispatus CTV-05
Study Locations (4)
California
- University of California, San Diego - Antiviral Research Center - San Diego
- San Francisco General Hospital - Infectious Diseases - San Francisco
Illinois
- Cook County Health and Hospitals System - Ruth M Rothstein CORE Center - Chicago
Missouri
- Washington University School of Medicine in St. Louis - Infectious Disease Clinical Research Unit - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2016-06-03 |
| Est. Completion | 2019-02-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02766023
The ClinicalTrials.gov registry entry for NCT02766023 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 228 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 323-participant average among 15 other Bacterial Vaginosis trials with a reported enrollment target (29% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bacterial Vaginosis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02766023 reports 4 study locations spanning 3 distinct geographic areas - top geographies include California, Illinois, Missouri.
Frequently Asked Questions
What is clinical trial NCT02766023 about?
NCT02766023 is a clinical study titled "LACTIN-V Study for Recurrent Bacterial Vaginosis". This Phase 2b trial is designed to provide a screening evaluation for the hypothesis that, following a 5-day treatment with MetroGel® to treat BV, L. crispatus CTV-05 (LACTIN-V, Osel, Inc.) administered at 2 x 10\^9 cfu/dose using a vaginal applicator reduces the 12-week incidence of BV recurrence w...
What is the current status of trial NCT02766023?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 228 participants. The study started on 2016-06-03. Estimated completion is 2019-02-11.
What conditions does trial NCT02766023 study?
This clinical trial studies the following conditions: Bacterial Vaginosis.
What interventions are being tested in trial NCT02766023?
The interventions under investigation include: Placebo (OTHER), Metronidazole (DRUG), Lactobacillus crispatus CTV-05 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02766023?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02766023 being conducted?
This trial has 4 study locations across California, Illinois, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bacterial Vaginosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Single Arm Trial of Menstrual Cups Among Economically Vulnerable Women to Reduce Bacterial Vaginosis and STIs
ACTIVE NOT RECRUITING · Phase 2
-
Suppression Of Bacterial Vaginosis (BV) [SUBVert]
COMPLETED · Phase 2
-
Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women
COMPLETED · Phase 2
-
Clinical Protocol CERN Feasibility Study
RECRUITING · NA
-
Prospective Data Bank Creation to Study Vaginal Conditions
RECRUITING
-
Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.